Skip to main content

Table 7 Tacrolimus pharmacokinetic data in relation to CYP3A5 gene polymorphisms in the 8 patients with acute rejection (AR)

From: CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant

 

Days

AA/AG with AR (5 patients)

GG with AR (3 patients)

AA/AG without AR (7 patients)

Dose/kg (mg/kg)

day 7

0.14 ± 0.01

0.11 ± 0.05

0.19 ± 0.14

day 30

0.20 ± 0.03*

0.09 ± 0.03

0.18 ± 0.13

day 90

0.14 ± 0.05*

0.08 ± 0.01

0.16 ± 0.12

day 80

0.13 ± 0.04*

0.06 ± 0.01

0.14 ± 0.10

day 360

0.10 ± 0.04

0.05 ± 0.02

0.13 ± 0.10

C0/(dose/kg) (ng/ml)/(mg/kg)

day 7

55.56 ± 20.87

175.42 ± 120.49

74.92 ± 62.45

day 30

45.81 ± 10.91 *#

105.81 ± 47.40

92.53 ± 49.62

day 90

63.92 ± 26.57*#

126.11 ± 54.57

110.56 ± 55.25

day 180

55.33 ± 23.42*

134.14 ± 77.98

79.78 ± 35.21

day 360

79.48 ± 49.34

121.85 ± 50.87

66.35 ± 37.25

  1. Data are expressed as mean ± s.d. Mann Whitney was used as statistical test
  2. * p-value < 0.05 AA/AG vs GG patients with acute rejections
  3. # p-value < 0.05 AA/Ag with acute rejection vs AA/AG without acute rejection
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us